Why the study?
Does methylprednisolone prevent progressive myocardial dysfunction resulting from experimental coronary microembolization in dogs?
Population
27 dogs subjected to experimental coronary microembolization via injection of 42-microm diameter…
Comparison
Methylprednisolone 30 mg/kg IV given either 30… vs Placebo
Design
Preclinical
Follow-up
8 hours (acute group) and 1 week (chronic group)
Key result
Methylprednisolone (30 mg/kg IV) prevented progressive myocardial contractile dysfunction when given before or after experimental coronary microembolization in dogs.
Authors
Loading...
Does not support clinical use; leaves open translation of post-event efficacy from this canine model to patients.
Does methylprednisolone prevent progressive myocardial dysfunction resulting from experimental coronary microembolization in dogs?
Methylprednisolone prevents progressive contractile dysfunction following experimental coronary microembolization in dogs, even when administered after the event.
Skyschally et al. (2004) studied Experimental coronary microembolization (n=27). Methylprednisolone vs. Placebo was evaluated on Posterior systolic wall thickening. Methylprednisolone (30 mg/kg IV) prevented progressive myocardial contractile dysfunction when given before or after experimental coronary microembolization in dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: